IsoRay Applauds Cleveland Clinic Prostate Study Conclusions On Brachytherapy Superiority

IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, said today that the findings of a Cleveland Clinic study adds to the continuing evidence supporting the efficacy of brachytherapy. The Cleveland Clinic study compared external beam radiation, prostatectomy (the surgical removal of the prostate) and brachytherapy (internal radiation therapy). The study, which examined the treatment outcomes for 137,000 men over a five year period, found brachytherapy to have the fewest number of toxicities involving genital or urinary organs and had the lowest total cost per patient per year. The Cleveland Clinic researchers are the first to examine the quality of life and financial costs of the three most common prostate cancer treatments over a prolonged period after treatment.

IsoRay CEO Dwight Babcock said the study findings are no surprise. "The results are confirmation of what we have known at IsoRay for some time. Brachytherapy low dose internal radiation is the most effective and cost efficient therapy available, along with having the fewest complications. Importantly, we are the only brachytherapy company with an isotope (Cesium-131) that has enough energy and the short half life needed to combat fast growing, aggressive cancers located anywhere in the body. Going forward, it is my hope that this study will serve to shift the focus back to brachytherapy as physicians receive further confirmation of its superiority."

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. Cs-131 seeds deliver radiation quickly and aggressively compared to other types of internal, low dose rate radiation. Brachytherapy with Cs-131 is minimally invasive, provides higher energy, more rapidly delivers a uniform dose of radiation, and has a shorter half life (9.7 days) than other radioactive isotopes used in internal radiation therapy. The ground-breaking treatment impacts longevity and cure rates, can be performed outside a hospital setting, and results in a patient's faster return to normal activities.

Babcock says he strongly believes the expected upcoming release of IsoRay's 5 year data on the use of Cesium-131 to treat prostate cancer will provide further compelling evidence for doctors and the patients they treat regarding the choice of Cesium-131. "While for quite some time we have known our isotope Cesium-131 has been performing better than other treatments, we now have our 5 year data being peer reviewed, providing factual evidence supporting the claims of independent medical professionals that we have the best performing brachytherapy seed for prostate cancer on the market. Current data already proves we are superior in both energy and having patients return to baseline faster following treatment." Babcock says that he also expects a number of significant developments in the months ahead regarding further progress in current initiatives and ongoing discussions relative to the application of Cesium-131 for treating cancers in other body sites including breast, pancreatic, and esophageal cancers.

In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of prostate, lung, ocular melanoma, brain, colorectal, gynecological, and head and neck cancer and other cancers throughout the body.

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 Brachytherapy seeds, which are expanding Brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com .

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the expected outcomes from the 5 year Cs-131 study, whether IsoRay will be able to continue to expand its base beyond prostate cancer to treat additional cancers and malignant disease, whether the use of Cesium-131 to treat other cancers will be successful in the initial and any future implants, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX